Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Subjects with the rare autosomal dominant disease Hereditary Hemorrhagic Telangiectasia (HHT) may develop medical conditions that require antithrombotic therapy (AT). However, safety of AT is uncertain in these patients and the only data currently available derive from retrospective analyses of regi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Orphanet J Rare Dis
Main Authors: Gaetani, Eleonora, Agostini, Fabiana, Porfidia, Angelo, Giarretta, Igor, Feliciani, Daniela, Di Martino, Luigi, Tortora, Annalisa, Gasbarrini, Antonio, Pola, Roberto
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6933630/
https://ncbi.nlm.nih.gov/pubmed/31878955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-019-1278-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados